Last reviewed: June 17, 2026
Last updated: June 17, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Zepbound (tirzepatide) has transformed weight management for millions, but strict FDA eligibility criteria limit access for many patients who could benefit. Understanding these requirements—and knowing your alternatives—helps you make informed decisions about GLP-1 therapy.
BMI Thresholds and Weight Loss Criteria for Zepbound
The FDA requires a Body Mass Index (BMI) of 30 or higher for Zepbound eligibility, or 27 or higher if you have a weight-related comorbidity like type 2 diabetes or hypertension. Additionally, patients must demonstrate a documented history of at least one weight loss attempt through lifestyle modification. These thresholds create barriers for people just below BMI 30 who still struggle with weight management and metabolic health.
Weight loss expectations matter too: clinical trials showed Zepbound users lost 21% of baseline body weight over 68 weeks with the highest dose. However, individual results vary significantly based on genetics, adherence, and metabolic factors. PlexusDx's Precision Peptide Genetic Test identifies your unique GLP1R and GIPR variants to predict personalized response patterns before starting therapy.
Medical History Factors That May Disqualify Zepbound
Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) is an absolute contraindication for Zepbound and all GLP-1 agonists. A history of severe pancreatitis, active suicidal ideation, or certain diabetic retinopathy complications also requires careful evaluation with your provider before starting any tirzepatide therapy.
Pregnancy, breastfeeding, and recent GI surgery are additional exclusion criteria. Some patients with gastroparesis, severe GERD, or inflammatory bowel disease may not qualify. These restrictions exist because clinical trial data remains limited in these populations, not necessarily because tirzepatide causes direct harm. Your individual medical history determines whether Zepbound or a compounded alternative fits your specific situation.
Why PlexusDx Tirzepatide Offers Broader Access
PlexusDx compounded tirzepatide injection (starting at $249/month) serves patients who fall outside Zepbound's rigid eligibility framework. Because compounded tirzepatide comes from licensed 503A pharmacies rather than following FDA brand restrictions, prescribing decisions rest with your PlexusDx-affiliated physician based on your unique health profile. This means patients with BMI between 25–30, prior failed weight loss attempts, or specific comorbidities can still access tirzepatide therapy with personalized dosing guidance.
No insurance requirement, no membership fees, and HSA/FSA eligibility make compounded tirzepatide financially accessible regardless of employment status or coverage gaps. Your dose may need to go up. Your price won't—PlexusDx pricing remains flat across all commitment tiers, eliminating the cost anxiety that often prevents people from optimizing their therapy.
Genetic Testing to Optimize Your Tirzepatide Response
Even if you meet Zepbound criteria, knowing your genetic predisposition to GLP-1 responsiveness transforms treatment outcomes. PlexusDx's Precision Peptide Genetic Test ($99 add-on after your first month) analyzes 14 metabolic pathways and 150+ genetic insights, including critical variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These genetic markers predict how your body will respond to tirzepatide before you invest weeks in a therapy that may underperform.
Patients with favorable GLP1R variants typically show robust appetite suppression and sustained weight loss, while those with certain FTO and MC4R variants may require combination strategies or dose optimization. This precision approach—unavailable with standard Zepbound prescribing—helps PlexusDx patients achieve 25–35% weight loss within 6 months by starting with the right compound and dose for their genetics.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What if my BMI is 28 but I have type 2 diabetes—can I get Zepbound?
Yes, Zepbound eligibility includes BMI 27 or higher with weight-related comorbidities like diabetes. However, PlexusDx offers tirzepatide injections with more flexible prescribing based on your clinical picture and genetic metabolic profile, giving your physician more latitude to personalize therapy.
Are compounded tirzepatide from PlexusDx and Zepbound chemically identical?
Yes, compounded tirzepatide contains the same active ingredient as Zepbound. PlexusDx sources from licensed 503A compounding pharmacies that follow strict USP standards for purity and potency. The difference is regulatory classification, not chemical composition or efficacy.
How much weight loss can I expect with PlexusDx tirzepatide?
Clinical trials show average weight loss of 21–22% of baseline body weight over 68 weeks. Your personal results depend on genetics (identified through the Precision Peptide Genetic Test), adherence, diet, and exercise. PlexusDx patients using genetic insights report 25–35% weight loss within 6 months by optimizing their starting dose and compound.
Does PlexusDx tirzepatide work if I have a history of pancreatitis?
History of severe pancreatitis is a contraindication for GLP-1 therapy including tirzepatide. Your PlexusDx-affiliated physician will review your medical records carefully. If pancreatitis risk is moderate or your history is remote, your doctor may discuss benefits and monitoring, but this decision requires direct clinical evaluation.
What does the Precision Peptide Genetic Test actually measure?
PlexusDx's test analyzes your peptide-pathway genetics—not pharmacogenomics—mapping 14 metabolic pathways and 49 peptides to predict GLP-1 responsiveness. Key variants like GLP1R rs6923761 and GIPR rs1800437 show whether your body will have strong appetite suppression and sustained weight loss, allowing your physician to optimize your tirzepatide protocol from day one.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Quickly Do You Lose Weight on Ozempic?
Your First Step Towards a Healthier Future: What to Expect After Your First Dose of Zepbound